Compare Verquvo vs. Entresto

Verquvo (vericiguat) and Entresto (sacubitril / valsartan) are both medications used to treat heart failure, but they belong to different medication classes. Verquvo is a soluble guanylate cyclase (sGC) stimulator, while Entresto is an angiotensin receptor-neprilysin inhibitor (ARNI). Verquvo is taken once daily with food, while Entresto is taken twice daily. Additionally, Entresto is approved for both adults and children aged 1 year and older and Verquvo is only approved for adults. Both medications are only available as brand medications. Verquvo is available only as oral tablets, whereas Entresto is available as tablets, oral pellets, or a prepared oral solution. Common side effects of Verquvo include low blood pressure and anemia, while Entresto can cause low blood pressure, high potassium levels, and dizziness. Verquvo should not be taken with phosphodiesterase-5 inhibitors due to the risk of low blood pressure, whereas Entresto should not be combined with angiotensin II receptor blockers (ARBs), angiotensin-converting enzyme (ACE) inhibitors, or medications that raise potassium levels.